Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD

Journal of Neurology

Volumn 256, Issue SUPPL. 3, 2009, Pages

  Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acetylcholine; Dementia with Lewy bodies; Glutamate; Parkinson's disease dementia; Proteasome; Serotonin

Indexed keywords

ALPHA SYNUCLEIN; AMANTADINE; LEVODOPA; MEMANTINE; PROTEASOME; PROTEIN SUBUNIT; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SYNUCLEIN;

ALZHEIMER DISEASE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CATALYSIS; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DELUSION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DYSKINESIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; NERVE CELL NECROSIS; NERVE CONDUCTION; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSYCHOSIS; SEROTONINERGIC SYSTEM; VISUAL HALLUCINATION;

ALPHA-SYNUCLEIN; BRAIN; HUMANS; LEWY BODIES; LEWY BODY DISEASE; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN;

EID: 69549116778     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5247-7     Document Type: Conference Paper

References (56)

1. JL Albasanz E Dalfo I Ferrer M Martin 2005 Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes Neurobiol Dis 20 685 693
2. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry et al (1999) Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 156:1039-1045
3. C Ballard M Johnson M Piggott R Perry J O'Brien E Rowan E Perry P Lantos N Cairns C Holmes 2002 A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies J Affect Disord 69 219 223
4. C Ballard M Piggott M Johnson N Cairns R Perry I McKeith E Jaros J O'Brien C Holmes E Perry 2000 Delusions associated with elevated muscarinic binding in dementia with Lewy bodies Ann Neurol 48 868 876
5. L Bedford D Hay A Devoy S Paine DG Powe R Seth T Gray I Topham K Fone N Rezvani M Mee T Soane R Layfield PW Sheppard T Ebendal D Usoskin J Lowe RJ Mayer 2008 Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies J Neurosci 28 8189 8198
6. M Bhasin E Rowan K Edwards I McKeith 2007 Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis Int J Geriatr Psychiatry 22 890 895
7. K Bronnick D Aarsland JP Larsen 2005 Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia Acta Psychiatr Scand 112 201 207
8. Burton EJ, McKeith IG, Burn DJ, O'Brien JT (2005) Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 20:1571-1576
9. EJ Burton IG McKeith DJ Burn ED Williams JT OBrien 2004 Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls Brain 127 791 800
10. R Camicioli MM Moore A Kinney E Corbridge K Glassberg JA Kaye 2003 Parkinson's disease is associated with hippocampal atrophy Mov Disord 18 784 790
11. CPLH Chen JT Alder L Bray AE Kingsbury PT Francis OJF Foster 1998 Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex Adv Serotonin Recept Res Mol Biol Signal Transduct Ther 861 288 289
12. J Court C Martin-Ruiz M Piggott D Spurden M Griffiths E Perry 2001 Nicotinic receptor abnormalities in Alzheimer's disease Biol Psychiatry 49 175 184
13. Crosby N, Deane KH, Clarke CE (2003) Amantadine in Parkinson's disease. Cochrane Database Syst Rev CD003468
14. Crosby NJ, Deane KH, Clarke CE (2003) Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev CD003467
15. RJ D'Amato RM Zweig PJ Whitehouse GL Wenk HS Singer R Mayeux DL Price SH Snyder 1987 Aminergic systems in Alzheimer's disease and Parkinson's disease Ann Neurol 22 229 236
16. W Danysz CG Parsons J Kornhuber WJ Schmidt G Quack 1997 Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies Neurosci Biobehav Rev 21 455 468
17. KL Double GM Halliday DA McRitchie WG Reid MA Hely JG Morris 1996 Regional brain atrophy in idiopathic Parkinson's disease and diffuse Lewy body disease Dementia 7 304 313
18. Emmanouilidou E, Stefanis L, Vekrellis K (2008) Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2008.07.008
19. M Emre D Aarsland A Albanese EJ Byrne G Deuschl PP De Deyn F Durif J Kulisevsky T van Laar A Lees W Poewe A Robillard MM Rosa E Wolters P Quarg S Tekin R Lane 2004 Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 351 2509 2518 (Pubitemid 39603164)
20. PT Francis 2003 Glutamatergic systems in Alzheimer's disease Int J Geriat Psychiatry 18 S15 S21
21. PT Francis AM Palmer M Snape GK Wilcock 1999 The cholinergic hypothesis of Alzheimer's disease: a review of progress J Neurol Neurosurg Psychiatry 66 137 147
22. CG Goetz W Poewe O Rascol C Sampaio 2005 Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001-2004 Mov Disord 20 523 539
23. GM Halliday YW Li PC Blumbergs TH Joh RG Cotton PR Howe WW Blessing LB Geffen 1990 Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease Ann Neurol 27 373 385
24. HA Hanagasi M Emre 2005 Treatment of behavioural symptoms and dementia in Parkinson's disease Fundam Clin Pharmacol 19 133 146 (Pubitemid 40524112)
25. LA Hansen SE Daniel GK Wilcock S Love 1998 Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia J Neurol Neurosurg Psychiatry 64 653 656
26. P Hantz G Caradoc-Davies T Caradoc-Davies M Weatherall G Dixon 1994 Depression in Parkinson's disease Am J Psychiatry 151 1010 1014
27. A Kashani C Betancur B Giros E Hirsch SE Mestikawy 2006 Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease Neurobiol Aging 28 568 578
28. ML Kramer WJ Schulz-Schaeffer 2007 Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies J Neurosci 27 1405 1410
29. W Kuhn T Muller M Gerlach E Sofic G Fuchs N Heye R Prautsch H Przuntek 1996 Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients J Neural Transm 103 1441 1445
30. MP Laakso K Partanen P Riekkinen M Lehtovirta EL Helkala M Hallikainen T Hanninen P Vainio H Soininen 1996 Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study Neurology 46 678 681
31. I Litvan E Mohr J Williams C Gomez TN Chase 1991 Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease J Neurol Neurosurg Psychiatry 54 25 29
32. CW Liu BI Giasson KA Lewis VM Lee GN Demartino PJ Thomas 2005 A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease J Biol Chem 280 22670 22678
33. C Martin-Ruiz J Court M Lee M Piggott M Johnson C Ballard R Kalaria R Perry E Perry 2000 Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types Acta Neurol Scand Suppl 176 34 41 (Pubitemid 32156168)
34. R Mayeux Y Stern M Sano JB Williams LJ Cote 1988 The relationship of serotonin to depression in Parkinson's disease Mov Disord 3 237 244
35. IG McKeith JB Grace Z Walker EJ Byrne D Wilkinson T Stevens EK Perry 2000 Rivastigmine in the treatment of dementia with lewy bodies: preliminary findings from an open trial Int J Geriat Psychiatry 15 387 392
36. KS McNaught R Belizaire O Isacson P Jenner CW Olanow 2003 Altered proteasomal function in sporadic Parkinson's disease Exp Neurol 179 38 46
37. KS McNaught CW Olanow B Halliwell O Isacson P Jenner 2001 Failure of the ubiquitin-proteasome system in Parkinson's disease Nat Rev Neurosci 2 589 594
38. M Merello MI Nouzeilles A Cammarota R Leiguarda 1999 Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study Clin Neuropharmacol 22 273 276
39. EK Perry JM Kerwin RH Perry D Irving G Blessed AF Fairbairn 1990 Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type Dementia 1 2 4
40. EK Perry E Marshall J Kerwin CJ Smith S Jabeen AV Cheng RH Perry 1990 Evidence of a monoaminergic cholinergic imbalance related to visual hallucinations in Lewy body dementia J Neurochem 55 1454 1456
41. EK Perry CM Morris JA Court A Cheng AF Fairbairn IG McKeith D Irving A Brown RH Perry 1995 Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's: possible index of early neuropathology Neuroscience 64 385 395
42. M Rechsteiner CP Hill 2005 Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors Trends Cell Biol 15 27 33
43. RT Reid MN Sabbagh J Corey-Bloom P Tiraboschi LJ Thal 2000 Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease Neurobiol Aging 21 741 746
44. B Reisberg R Doody A Stoffler F Schmitt S Ferris HJ Mobius 2003 Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 1333 1341
45. BH Ridha KA Josephs MN Rossor 2005 Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine Neurology 65 481 482
46. MN Sabbagh AM Hake S Ahmed MR Farlow 2005 The use of memantine in dementia with Lewy bodies J Alzheimers Dis 7 285 289
47. B Scatton F Javoy-Agid L Rouquier B Dubois Y Agid 1983 Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease Brain Res 275 321 328
48. Scott HL, Pow DV, Tannenberg AE, Dodd PR (2002) Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci 22:(RC206):1-5
49. Sharp SI, Ballard CG, Ziabreva I, Perry EK, Aarsland D, Larsen JP, Francis PT (2005) Sertonin-1A receptor binding to frontal cortex in dementia with Lewy bodies and Parkinson's disease dementia. pA2 (Ejournal of the British Pharmacological Society) v2 p65 (abstract)
50. SI Sharp CG Ballard I Ziabreva MA Piggott RH Perry EK Perry D Aarsland U Ehrt JP Larsen PT Francis 2008 Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia Dement Geriatr Cogn Disord 26 330 338
51. K Shiozaki E Iseki H Hino K Kosaka 2001 Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study J Neurol Sci 193 23 28
52. K Shiozaki E Iseki H Uchiyama Y Watanabe T Haga K Kameyama T Ikeda T Yamamoto K Kosaka 1999 Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease J Neurol Neurosurg Psychiatry 67 209 213
53. V Thorns M Mallory L Hansen E Masliah 1997 Alterations in glutamate receptor 2/3 subunits and amyloid precursor protein expression during the course of Alzheimer's disease and Lewy body variant Acta Neuropathol (Berl) 94 539 548
54. P Tiraboschi LA Hansen M Alford A Merdes E Masliah LJ Thal J Corey-Bloom 2002 Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease Arch Gen Psychiatry 59 946 951
55. Y Tsuboi DW Dickson 2005 Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord 11 Suppl 1 S47 S51
56. S Wonnacott 1997 Presynaptic nicotinic ACh receptors Trends Neurosci 20 92 98